Alivus Life Sciences 15th AGM Approves Dividend and Growth Strategy
Alivus Life Sciences Ltd 路 Annual General Meeting 路 09 Sept 2026, 1:49 am
Alivus Life Sciences 15th AGM Approves Dividend and Growth Strategy Alivus Life Sciences concluded its 15th AGM on 8th Sep'26, passing all four ordinary resolutions with requisite majorities. Key approvals include the FY26 audited financial statements, a final dividend of Rs. 5 per equity share, the reappointment of Director Hiren Patel, and the ratification of Cost Auditor remuneration for FY27. Management highlighted FY26 revenue growth, record profitability, and strong cash generation while detailing future expansion driven by an "API+" strategy and continued investments in manufacturing, R&D, and advanced pharmaceutical capabilities.
Original exchange filing (PDF)
More announcements from Alivus Life Sciences Ltd
- Enclosed please find herewith update on acquisition. 路 11 Nov 2026
- Please find enclosed herewith disclosure under Regulation 30 of SEBI(LODR), 2015. 路 11 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirma Ltd 路 07 Nov 2026
- Please find attached herewith submission with respect to transcript of the earning call. 路 06 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor meeting. 路 04 Nov 2026
- Please find enclosed herewith intimation for Analyst/Investor Meet. 路 30 Oct 2026
- We hereby confirm that we have uploaded audio recording of the Q2 FY2027 Earnings Call held on October 30, 2026 on the website of the Company. 路 30 Oct 2026
- Please find enclosed herewith intimation with respect to allotment of equity shares under "Employee Stock Option Scheme, 2021" 路 30 Oct 2026
